Syndromic STI Management Remains Essential in Remote Amazon, 10-Year Study Shows

In the Brazilian Amazon, where rivers replace roads and some communities can only be reached by boat or plane, a decade of patient records tells a story about how medicine adapts when laboratories are far away. Researchers at a major referral center in Manaus reviewed more than 32,000 patient visits over ten years and found that doctors there have relied on a deceptively simple strategy: look at what the patient shows you, treat based on symptoms, and move forward without waiting for test results that might never arrive.

This approach, called syndromic management, has become essential in places where infrastructure fails to keep pace with need. The study, published in May 2026, documents how often this method was used and who walked through the clinic doors. Nearly 15,000 syndromic diagnoses were recorded among the 32,485 patients who sought care. Genital warts accounted for 41 percent of cases, followed by urethral discharge at 31.5 percent, genital ulcers at 21.3 percent, and cervical and vaginal discharge making up the remainder. The numbers are large, but they tell a smaller story: men showed up far more often than women, accounting for 71.5 percent of all diagnoses.

When researchers looked at who was most likely to receive these diagnoses, certain patterns emerged with statistical clarity. Men were 2.3 times more likely than women to be diagnosed syndromically. Single people were 1.8 times more likely than those in relationships. People over 30 carried slightly elevated odds. But the strongest associations came from behavior: those who used condoms inconsistently were 3.2 times more likely to be diagnosed, and people with two or more casual partners were 3.4 times more likely. Nearly 30 percent of patients reported never using condoms. More than 40 percent said their first sexual encounter happened at age 15 or younger.

Behind these percentages lies a public health reality that numbers alone cannot convey. Among the 22,160 patients tested for HIV and syphilis during routine care, 1,685 tested positive for HIV—a 7.6 percent rate. For syphilis, the figure was even higher: 4,363 people, or 19.7 percent of those tested. These are not abstract epidemiological markers. They represent people in a region where a syphilis detection rate of 93.7 cases per 100,000 inhabitants in 2023 far exceeded national averages, where geographic isolation compounds the difficulty of follow-up care, and where indigenous and riverside populations face particular structural barriers to prevention and treatment.

The study's findings are shaped by the landscape itself. The Amazon's vast territory, with communities scattered across waterways and dense forest, makes it nearly impossible to implement the kind of laboratory-based diagnosis that has become standard in wealthier regions. A patient cannot easily return for test results when the clinic is days away by river. A healthcare worker cannot easily access supply chains for rapid tests when infrastructure is thin. In this context, syndromic management is not a choice born of preference—it is a pragmatic necessity, a way to ensure that someone with symptoms receives treatment on the day they appear, rather than risk losing them to the distances and delays that characterize care in remote settings.

Yet the researchers are careful to note that necessity does not mean adequacy. Syndromic management has real limitations. Without laboratory confirmation, doctors may overtreat, exposing patients to unnecessary antibiotics and contributing to the growing problem of antimicrobial resistance. They may misdiagnose, missing infections that require different approaches. The World Health Organization has increasingly recommended moving away from exclusive reliance on symptom-based treatment and toward integration with rapid tests and molecular diagnostics wherever feasible. Brazil's own health ministry now emphasizes combining syndromic assessment with rapid testing for HIV and syphilis, a hybrid approach that could improve accuracy without sacrificing the speed that remote settings demand.

The data itself shows a dip during 2020 and 2021, almost certainly reflecting the COVID-19 pandemic's disruption of healthcare-seeking behavior rather than any true decline in infection rates. Looking forward, the researchers suggest that the Amazon's unique challenges demand equally tailored solutions: mobile clinics that travel by river, telehealth-supported follow-up for patients in isolated areas, point-of-care testing integrated directly into syndromic consultations, and strengthened partner notification systems. The goal is not to abandon syndromic management but to embed it within a more complete diagnostic and surveillance infrastructure—one that acknowledges both the realities of geography and the imperative to do better.